masterplex qt curve-fitting software Search Results


masterplex readerfit  (Miraibio Inc)
90
Miraibio Inc masterplex readerfit
LF interacts with Plg. A, LF, Plg, and BSA (as a negative control), coated on wells of a plastic plate (5 μg/ml), were incubated for 4 h on ice with purified M6P/IGF2R (5 μg/ml) in the absence or presence of additional molecules: mannose 1-phosphate (M1P) and M6P (both 10 mmol/liter), soluble uPAR (5 μg/ml), Plg (50 and 100 nmol/liter), or LF (20 and 40 μg/ml). Bound material was analyzed by immunoblotting (IB) using the specific mAb MEM-238 to M6P/IGF2R. B, coated Plg or BSA (5 μg/ml) was incubated for 4 h on ice with LF (20 μg/ml). Before LF was added, some wells were pre-incubated for 2 h on ice with 20 μg/ml LF-derived peptides (pLF1, pLF2, or pLF3) and scrambled peptide (pSCR) or 5 mmol/liter tranexamic acid (TA). Bound material was analyzed by immunoblotting using human LF-specific mAb 4E2. C, the binding assay was performed as in B but with the pre-incubation with increasing concentrations of pLF1 or scrambled peptide pSCR as indicated. D and E, densitometric quantifications of LF binding assays. A representative immunoblot is shown in B and in C and D, respectively. Bars, relative means with S.D. (error bars) of at least three independent experiments. The scrambled peptide pSCR served as a control, and the corresponding bands were set as a relative maximum of 100%. Immunoblots were quantified with Fuji MultiGauge software. Bands corresponding to LF binding to BSA were subtracted from the bands of LF binding to Plg bands; in addition, a background correction for each individual lane was applied. The relative IC50 value was determined by a 4PL nonlinear regression curve fit, in accordance with National Institutes of Health assay guidance (64). Curve fitting was performed with <t>MasterPlex</t> <t>ReaderFit,</t> published by the MiraiBio Group of Hitachi Software Engineering America, Ltd. F, the binding assay was performed as in B, but Plg and the Plg fragments angiostatin, mini-Plg, and micro-Plg, or BSA, were coated onto plastic wells. Optionally, the binding assay was performed in the presence of Triton X-100 (0.1%). G, densitometric quantification was performed as in D and E. A representative immunoblot is shown in F, without the detergent; *, p < 0.05; **, p < 0.005.
Masterplex Readerfit, supplied by Miraibio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/masterplex readerfit/product/Miraibio Inc
Average 90 stars, based on 1 article reviews
masterplex readerfit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
masterplex qt 2010  (Miraibio Inc)
90
Miraibio Inc masterplex qt 2010
LF interacts with Plg. A, LF, Plg, and BSA (as a negative control), coated on wells of a plastic plate (5 μg/ml), were incubated for 4 h on ice with purified M6P/IGF2R (5 μg/ml) in the absence or presence of additional molecules: mannose 1-phosphate (M1P) and M6P (both 10 mmol/liter), soluble uPAR (5 μg/ml), Plg (50 and 100 nmol/liter), or LF (20 and 40 μg/ml). Bound material was analyzed by immunoblotting (IB) using the specific mAb MEM-238 to M6P/IGF2R. B, coated Plg or BSA (5 μg/ml) was incubated for 4 h on ice with LF (20 μg/ml). Before LF was added, some wells were pre-incubated for 2 h on ice with 20 μg/ml LF-derived peptides (pLF1, pLF2, or pLF3) and scrambled peptide (pSCR) or 5 mmol/liter tranexamic acid (TA). Bound material was analyzed by immunoblotting using human LF-specific mAb 4E2. C, the binding assay was performed as in B but with the pre-incubation with increasing concentrations of pLF1 or scrambled peptide pSCR as indicated. D and E, densitometric quantifications of LF binding assays. A representative immunoblot is shown in B and in C and D, respectively. Bars, relative means with S.D. (error bars) of at least three independent experiments. The scrambled peptide pSCR served as a control, and the corresponding bands were set as a relative maximum of 100%. Immunoblots were quantified with Fuji MultiGauge software. Bands corresponding to LF binding to BSA were subtracted from the bands of LF binding to Plg bands; in addition, a background correction for each individual lane was applied. The relative IC50 value was determined by a 4PL nonlinear regression curve fit, in accordance with National Institutes of Health assay guidance (64). Curve fitting was performed with <t>MasterPlex</t> <t>ReaderFit,</t> published by the MiraiBio Group of Hitachi Software Engineering America, Ltd. F, the binding assay was performed as in B, but Plg and the Plg fragments angiostatin, mini-Plg, and micro-Plg, or BSA, were coated onto plastic wells. Optionally, the binding assay was performed in the presence of Triton X-100 (0.1%). G, densitometric quantification was performed as in D and E. A representative immunoblot is shown in F, without the detergent; *, p < 0.05; **, p < 0.005.
Masterplex Qt 2010, supplied by Miraibio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/masterplex qt 2010/product/Miraibio Inc
Average 90 stars, based on 1 article reviews
masterplex qt 2010 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
masterplex qt quantitation software  (Miraibio Inc)
90
Miraibio Inc masterplex qt quantitation software
LF interacts with Plg. A, LF, Plg, and BSA (as a negative control), coated on wells of a plastic plate (5 μg/ml), were incubated for 4 h on ice with purified M6P/IGF2R (5 μg/ml) in the absence or presence of additional molecules: mannose 1-phosphate (M1P) and M6P (both 10 mmol/liter), soluble uPAR (5 μg/ml), Plg (50 and 100 nmol/liter), or LF (20 and 40 μg/ml). Bound material was analyzed by immunoblotting (IB) using the specific mAb MEM-238 to M6P/IGF2R. B, coated Plg or BSA (5 μg/ml) was incubated for 4 h on ice with LF (20 μg/ml). Before LF was added, some wells were pre-incubated for 2 h on ice with 20 μg/ml LF-derived peptides (pLF1, pLF2, or pLF3) and scrambled peptide (pSCR) or 5 mmol/liter tranexamic acid (TA). Bound material was analyzed by immunoblotting using human LF-specific mAb 4E2. C, the binding assay was performed as in B but with the pre-incubation with increasing concentrations of pLF1 or scrambled peptide pSCR as indicated. D and E, densitometric quantifications of LF binding assays. A representative immunoblot is shown in B and in C and D, respectively. Bars, relative means with S.D. (error bars) of at least three independent experiments. The scrambled peptide pSCR served as a control, and the corresponding bands were set as a relative maximum of 100%. Immunoblots were quantified with Fuji MultiGauge software. Bands corresponding to LF binding to BSA were subtracted from the bands of LF binding to Plg bands; in addition, a background correction for each individual lane was applied. The relative IC50 value was determined by a 4PL nonlinear regression curve fit, in accordance with National Institutes of Health assay guidance (64). Curve fitting was performed with <t>MasterPlex</t> <t>ReaderFit,</t> published by the MiraiBio Group of Hitachi Software Engineering America, Ltd. F, the binding assay was performed as in B, but Plg and the Plg fragments angiostatin, mini-Plg, and micro-Plg, or BSA, were coated onto plastic wells. Optionally, the binding assay was performed in the presence of Triton X-100 (0.1%). G, densitometric quantification was performed as in D and E. A representative immunoblot is shown in F, without the detergent; *, p < 0.05; **, p < 0.005.
Masterplex Qt Quantitation Software, supplied by Miraibio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/masterplex qt quantitation software/product/Miraibio Inc
Average 90 stars, based on 1 article reviews
masterplex qt quantitation software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
four-parameter curve fitting software  (Miraibio Inc)
90
Miraibio Inc four-parameter curve fitting software
LF interacts with Plg. A, LF, Plg, and BSA (as a negative control), coated on wells of a plastic plate (5 μg/ml), were incubated for 4 h on ice with purified M6P/IGF2R (5 μg/ml) in the absence or presence of additional molecules: mannose 1-phosphate (M1P) and M6P (both 10 mmol/liter), soluble uPAR (5 μg/ml), Plg (50 and 100 nmol/liter), or LF (20 and 40 μg/ml). Bound material was analyzed by immunoblotting (IB) using the specific mAb MEM-238 to M6P/IGF2R. B, coated Plg or BSA (5 μg/ml) was incubated for 4 h on ice with LF (20 μg/ml). Before LF was added, some wells were pre-incubated for 2 h on ice with 20 μg/ml LF-derived peptides (pLF1, pLF2, or pLF3) and scrambled peptide (pSCR) or 5 mmol/liter tranexamic acid (TA). Bound material was analyzed by immunoblotting using human LF-specific mAb 4E2. C, the binding assay was performed as in B but with the pre-incubation with increasing concentrations of pLF1 or scrambled peptide pSCR as indicated. D and E, densitometric quantifications of LF binding assays. A representative immunoblot is shown in B and in C and D, respectively. Bars, relative means with S.D. (error bars) of at least three independent experiments. The scrambled peptide pSCR served as a control, and the corresponding bands were set as a relative maximum of 100%. Immunoblots were quantified with Fuji MultiGauge software. Bands corresponding to LF binding to BSA were subtracted from the bands of LF binding to Plg bands; in addition, a background correction for each individual lane was applied. The relative IC50 value was determined by a 4PL nonlinear regression curve fit, in accordance with National Institutes of Health assay guidance (64). Curve fitting was performed with <t>MasterPlex</t> <t>ReaderFit,</t> published by the MiraiBio Group of Hitachi Software Engineering America, Ltd. F, the binding assay was performed as in B, but Plg and the Plg fragments angiostatin, mini-Plg, and micro-Plg, or BSA, were coated onto plastic wells. Optionally, the binding assay was performed in the presence of Triton X-100 (0.1%). G, densitometric quantification was performed as in D and E. A representative immunoblot is shown in F, without the detergent; *, p < 0.05; **, p < 0.005.
Four Parameter Curve Fitting Software, supplied by Miraibio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/four-parameter curve fitting software/product/Miraibio Inc
Average 90 stars, based on 1 article reviews
four-parameter curve fitting software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


LF interacts with Plg. A, LF, Plg, and BSA (as a negative control), coated on wells of a plastic plate (5 μg/ml), were incubated for 4 h on ice with purified M6P/IGF2R (5 μg/ml) in the absence or presence of additional molecules: mannose 1-phosphate (M1P) and M6P (both 10 mmol/liter), soluble uPAR (5 μg/ml), Plg (50 and 100 nmol/liter), or LF (20 and 40 μg/ml). Bound material was analyzed by immunoblotting (IB) using the specific mAb MEM-238 to M6P/IGF2R. B, coated Plg or BSA (5 μg/ml) was incubated for 4 h on ice with LF (20 μg/ml). Before LF was added, some wells were pre-incubated for 2 h on ice with 20 μg/ml LF-derived peptides (pLF1, pLF2, or pLF3) and scrambled peptide (pSCR) or 5 mmol/liter tranexamic acid (TA). Bound material was analyzed by immunoblotting using human LF-specific mAb 4E2. C, the binding assay was performed as in B but with the pre-incubation with increasing concentrations of pLF1 or scrambled peptide pSCR as indicated. D and E, densitometric quantifications of LF binding assays. A representative immunoblot is shown in B and in C and D, respectively. Bars, relative means with S.D. (error bars) of at least three independent experiments. The scrambled peptide pSCR served as a control, and the corresponding bands were set as a relative maximum of 100%. Immunoblots were quantified with Fuji MultiGauge software. Bands corresponding to LF binding to BSA were subtracted from the bands of LF binding to Plg bands; in addition, a background correction for each individual lane was applied. The relative IC50 value was determined by a 4PL nonlinear regression curve fit, in accordance with National Institutes of Health assay guidance (64). Curve fitting was performed with MasterPlex ReaderFit, published by the MiraiBio Group of Hitachi Software Engineering America, Ltd. F, the binding assay was performed as in B, but Plg and the Plg fragments angiostatin, mini-Plg, and micro-Plg, or BSA, were coated onto plastic wells. Optionally, the binding assay was performed in the presence of Triton X-100 (0.1%). G, densitometric quantification was performed as in D and E. A representative immunoblot is shown in F, without the detergent; *, p < 0.05; **, p < 0.005.

Journal: The Journal of Biological Chemistry

Article Title: Lactoferrin is a natural inhibitor of plasminogen activation

doi: 10.1074/jbc.RA118.003145

Figure Lengend Snippet: LF interacts with Plg. A, LF, Plg, and BSA (as a negative control), coated on wells of a plastic plate (5 μg/ml), were incubated for 4 h on ice with purified M6P/IGF2R (5 μg/ml) in the absence or presence of additional molecules: mannose 1-phosphate (M1P) and M6P (both 10 mmol/liter), soluble uPAR (5 μg/ml), Plg (50 and 100 nmol/liter), or LF (20 and 40 μg/ml). Bound material was analyzed by immunoblotting (IB) using the specific mAb MEM-238 to M6P/IGF2R. B, coated Plg or BSA (5 μg/ml) was incubated for 4 h on ice with LF (20 μg/ml). Before LF was added, some wells were pre-incubated for 2 h on ice with 20 μg/ml LF-derived peptides (pLF1, pLF2, or pLF3) and scrambled peptide (pSCR) or 5 mmol/liter tranexamic acid (TA). Bound material was analyzed by immunoblotting using human LF-specific mAb 4E2. C, the binding assay was performed as in B but with the pre-incubation with increasing concentrations of pLF1 or scrambled peptide pSCR as indicated. D and E, densitometric quantifications of LF binding assays. A representative immunoblot is shown in B and in C and D, respectively. Bars, relative means with S.D. (error bars) of at least three independent experiments. The scrambled peptide pSCR served as a control, and the corresponding bands were set as a relative maximum of 100%. Immunoblots were quantified with Fuji MultiGauge software. Bands corresponding to LF binding to BSA were subtracted from the bands of LF binding to Plg bands; in addition, a background correction for each individual lane was applied. The relative IC50 value was determined by a 4PL nonlinear regression curve fit, in accordance with National Institutes of Health assay guidance (64). Curve fitting was performed with MasterPlex ReaderFit, published by the MiraiBio Group of Hitachi Software Engineering America, Ltd. F, the binding assay was performed as in B, but Plg and the Plg fragments angiostatin, mini-Plg, and micro-Plg, or BSA, were coated onto plastic wells. Optionally, the binding assay was performed in the presence of Triton X-100 (0.1%). G, densitometric quantification was performed as in D and E. A representative immunoblot is shown in F, without the detergent; *, p < 0.05; **, p < 0.005.

Article Snippet: Curve fitting was performed with MasterPlex ReaderFit, published by the MiraiBio Group of Hitachi Software Engineering America, Ltd. F , the binding assay was performed as in B , but Plg and the Plg fragments angiostatin, mini-Plg, and micro-Plg, or BSA, were coated onto plastic wells.

Techniques: Negative Control, Incubation, Purification, Western Blot, Derivative Assay, Binding Assay, Software